2Henke BR, Heyer D. Recent advances in estrogen receptor modulators[J]. Curr Opin Drug Discov Devel , 2005, 8(4) :437 - 438.
3Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health[J]. Mol Aspects Med, 2006, 27 (4):299-402.
4Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant : overcoming endocrine [ J ]. Breast Cancer Res Treat, 2005, 93(Suppl 1 ) :S11 - S18.
5Jordan VC. Tamoxifen (IC146,474) as a targeted therapy to treat and prevent breast cancer [J]. Br J Pharmacol, 2006, 147 ( Suppl 1 ) : S269 - S276.
6Mansel R, Goyal A, Nestour EL, et al. A phase Ⅱ trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women [ J ]. Breast Cancer Res Treat, 2007, 106 (3) :389 - 397.
7Goss PE, Qi SL, Hu HQ. Comparing the effects of atamestane,toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats[J]. J Steroid Biochem Mol Biol, 2009, 113(3) :233 -240.
8Overk CR, Peng KW, Asghodom RT, et al. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene [J]. Chem Med Chem, 2007, 2(10) :1520 - 1526.
9Bolognese J, Krege WH, Utian WH, et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass [J]. J Clin Endocrinol Metab, 2009, 94(7) :2284 -2289.
10Al-Dhaheri MH, Shah YM, Basrur V, et al. Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells[J], Steroids, 2006, 71 ( 11/ 12) :966-978.
